What question did this study set out to answer?

Assess postprandial beta-cell function using mathematical modeling in patients with type 2 diabetes inadequately controlled with metformin with or without a sulfonylurea.

December 1, 2006Hormone and Metabolic Research

Mathematical Modeling Shows Exenatide Improved β-Cell Function in Patients with Type 2 Diabetes Treated with Metformin or Metformin and a Sulfonylurea

View Full Paper

Ask AI

Bookmark

Assess postprandial beta-cell function using mathematical modeling in patients with type 2 diabetes inadequately controlled with metformin with or without a sulfonylurea.
Randomized, placebo-controlled trial evaluating exenatide (5 µg twice daily for 4 weeks, then randomized to continue 5 µg, escalate to 10 µg, or receive placebo twice daily for 26 weeks) in patients maintained on metformin with or without a sulfonylurea.
Analyzed a subset of 73 patients who underwent meal tests at baseline and week 30 using mathematical modeling to assess dose-response, rate sensitivity, and potentiation independent of ambient glucose.
Model-predicted insulin secretion rate at a reference glucose level at week 30 increased 72% in the 10 µg group (p=0.015 vs placebo) and 40% in the 5 µg group (p=0.045 vs placebo), compared with a 21% decrease in the placebo group.
The 2-hour post-meal to basal potentiation factor ratio increased to 1.53 ± 0.10 with 10 µg (p=0.0142 vs placebo) and 1.40 ± 0.08 with 5 µg (p=0.0402 vs placebo), versus 1.15 ± 0.06 with placebo.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial demonstrates improved beta-cell function and insulin secretion in type 2 diabetes with exenatide, suggesting enhanced glycemic control independent of ambient glucose.

Cite This Study

Mari et al. (2006) studied this question.

synapsesocial.com/papers/6a70215cb5c1fe5ca9dfaa52 https://doi.org/10.1055/s-2006-956505

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates improved beta-cell function and insulin secretion in type 2 diabetes with exenatide, suggesting enhanced glycemic control independent of ambient glucose.

Mathematical Modeling Shows Exenatide Improved β-Cell Function in Patients with Type 2 Diabetes Treated with Metformin or Metformin and a Sulfonylurea

Key Points

Discussion

Implication

Cite This Study

Mathematical Modeling Shows Exenatide Improved β-Cell Function in Patients with Type 2 Diabetes Treated with Metformin or Metformin and a Sulfonylurea

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider